© Hogan & Hartson LLP. All rights reserved. Pharmaceutical Compliance Forum Clinical Trials Case Study Stephen J. Immelt Thursday, November 8, 2007.

Slides:

Advertisements

Similar presentations

© Hogan & Hartson LLP. All rights reserved. Second CIS Local Counsel Forum Park Inn Azerbaijan Hotel, Baku, Azerbaijan Tomasz Dobrowolski, Partner

Advertisements

© Hogan & Hartson LLP. All rights reserved. How We Get to Where We Want to Be – Managing GCP Inspections Pre-Approval Robert F. Church, Partner Hogan &

19 April 2012 The Office Agents Society Changes of Use from Commercial To Residential Michael Gallimore Hogan Lovells International LLP.

© 2009 Hogan & Hartson LLP. All rights reserved. Rebecca Armour April 2009 UK Rules on Corporate Expatriations Washington DC.

Art. 6 – 8 of the draft Unitary Patent Regulation Prof. Dr. Winfried Tilmann.

February 12, 2014 Life Sciences Enforcement Year in Review: Examining Hot Button Areas for FDA & Related Government Enforcement Peter Spivack, Hogan Lovells.

Legal Considerations When Doing Business in Australia Lisa Butler Admitted in Western Australia. Not Admitted in Texas. AACC Energy Conference 6 February.

Conflicts of Interest in Biomedical Research (A Brief History) PRIM&R Conference Boston, MA May 3, 2004 Barbara Mishkin Hogan & Hartson, L.L.P. 555 Thirteenth.

BEIJING BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG LONDON LOS ANGELES NEW YORK SAN FRANCISCO SHANGHAI SINGAPORE SYDNEY TOKYO WASHINGTON, D.C. What.

© Hogan & Hartson LLP. All rights reserved. NACD Capital Area Chapter Washington, DC September 9, 2008 Activist Hedge Funds in the Board Room: What Public.

Wireless Access Code: Download the agenda PDF at:

Subcommittee on Harmonization Mark Barnes David Forster.

16 July 2011 The Business Case for Mediation (for “ICC Arbitration & Amicable Dispute Resolution – Focus on India”) Jonathan Leach, partner, Hogan Lovells.

© Hogan & Hartson L.L.P. All rights reserved. JI and GIS: ERUs vs. Greened AAUs? A Legal Perspective Presentation at Project SKPI Workshop “Opportunities.

© 2013 Dechert LLP Defense Litigation Checklist September 26, 2013.

April 8, 2013 NPE litigation in Japan Activities and impact of FRAND commitments Eiichiro Kubota, Hogan Lovells Tokyo.

Understanding the GRAS Process Martin J. Hahn Hogan Lovells US LLP Date: July 16, 2013 Food and Agriculture Group.

January 2012 Workshop on competition law aspects International Legal Expert Meeting, January 2012 Leiden University, The Netherlands Jacques Derenne.

Recent developments in aviation liability & insurance: The 1973 Hague Convention on the law applicable to products liability: choice of law issues in aviation.

"The Role of Arbitration in the Dispensal of Justice" Does Arbitration Maintain the Advantages it Traditionally Enjoyed? Nathan Searle, Senior Associate.

Investing in Hotels in China: What You Need to Know The China Hotel Investment Summit 2005 April 2005 IMAGE HERE.

© 2009 Hogan & Hartson LLP. All rights reserved. Joseph A. Levitt Hogan & Hartson April 21, 2009 FDA Regulation of Bottled Water An Overview.

© 2009 Hogan & Hartson LLP. All rights reserved. ACCA-SoCal Chapter Roundtable “The Year that Privacy and Data Security Become Priority Risk Management.

Unfulfilled Promises: Affordable Housing in Metropolitan Washington Presentation to the Metropolitan Washington Council of Governments Mary Anne Sullivan,

Ethical Issues in Setting Litigation Reserves Clay James, Partner at Hogan Lovells Annie Kao, Senior Litigation Counsel at Vail Resorts December 8, 2010.

Chicago’s Global Status: Is Chicago a “global city”? GaWC: rates cities’ “global” status [Globalization and World Cities Study Group & Network: Loughborough.

Nicolas Pourbaix, Senior Associate

January 2012 Workshop on Radio Frequencies International Legal Expert Meeting, January 2012 Leiden University, The Netherlands Gerry Oberst.

Protection of Intellectual Property in the Customs Union of Russia, Belarus and Kazakhstan By Natalia Gulyaeva.

27 October 2011 Competitive dialogue in UK PFI PPP Forum Perspective Andrew Briggs, Partner.

© 2009 Hogan & Hartson LLP. All rights reserved. PENSION COMMITTEE v. BANC OF AMERICA SECS., LLC Diving Deeper Into the Zubulake Alvin F. Lindsay 24 February.

December 8, 2014 Healthcare/Privacy Current Law Affecting Uses of Health Data Melissa Bianchi Partner.

Hogan Lovells The solicitor's role Gathering the evidence –Disclosure in most cases: –Disclosure in most fraud cases: 1.

27 September 2013 Promoting Russia as a Seat of Arbitration: What Are the Best Ways Forward? Peter Pettibone.

© Hogan & Hartson LLP. All rights reserved. Transatlantic merger enforcement Catriona Hatton November 28, 2007 Brussels.

© Hogan & Hartson LLP. All rights reserved. The Evolving Standards For Defining “Exclusionary Conduct” in the United States Philip C. Larson November 28,

BEIJING BOSTON BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG HOUSTON LONDON LOS ANGELES NEW YORK PALO ALTO SAN FRANCISCO SHANGHAI SINGAPORE SYDNEY.

© Hogan & Hartson LLP. All rights reserved. Clinical Trials Track: Key Compliance Risks FDA Overview Meredith Manning November 8, 2007.

RESPONSIBLE CONDUCT IN HUMAN SUBJECTS RESEARCH MARGARITA M. CARDONA DIRECTOR OF SPONSORED RESEARCH Institutional Review Board.

Winston & Strawn LLP © 2007 CHICAGO GENEVA LONDON LOS ANGELES MOSCOW NEW YORK PARIS SAN FRANCISCO WASHINGTON, D.C. Institute of International Bankers Seminar.

© Hogan & Hartson LLP. All rights reserved. Alice Valder Curran, Partner Tuesday, October 17, 2006 Private Prices, Public Markets: The Evolution of Price.

Connecting the Dots A Practical Approach to Integrating Compliance, Risk and Quality Jody Ann Noon RN, JD Partner Health Care Regulatory Practice.

Mutuals' Forum 2010 Regulators & Legislators: Appreciating the Mutual Difference John Gilbert, Consultant 4 November 2010.

Institutional Review Board Issues for Classroom Research Sharon McWhorter IRB Administrator, The University of Akron (With assistance from Phil Allen,

© Hogan & Hartson LLP. All rights reserved. National Pharma Audioconference Bristol-Myers Squibb 2007 Settlement Stephen J. Immelt, Esq. November 26, 2007.

Alice Valder Curran, Partner October 28, 2008 Assessing Future Regulatory and Compliance Developments – The Current Landscape and Future Legislative Changes.

BEIJING BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG LONDON LOS ANGELES NEW YORK SAN FRANCISCO SHANGHAI SINGAPORE TOKYO WASHINGTON, D.C. Dawn raids.

BEIJING BRUSSELS CHICAGO DALLAS GENEVA HONG KONG LONDON LOS ANGELES NEW YORK SAN FRANCISCO SHANGHAI SINGAPORE TOKYO WASHINGTON D.C. What Pharmaceutical.

Russian response to US sanctions: what has been done and what to expect? 14 August 2014.

Agenda for Session Compliance in Clinical Research

November 2015 Presentation to South African Diamond Producers Organisation on Legal Liability Awareness – Introduction to the Mine Health & Safety Act.

© Hogan & Hartson LLP. All rights reserved. US Compliance Risks and Strategies: An Overview Stephen J. Immelt June 6, 2007 International Pharmaceutical.

© Hogan & Hartson LLP. All rights reserved. Cartels Fines, Leniency, Settlement John Pheasant November 28, 2007 Brussels.

© Hogan & Hartson LLP. All rights reserved. Catriona Hatton, Partner 26 May 2008 Medical Device Companies Antitrust Compliance Programmes.

© Hogan & Hartson LLP. All rights reserved. Monopoly Power: Getting it and keeping it US Perspective Sharis Pozen, Partner ACCE Seminar 13 May 2008.

BEIJING BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG LONDON LOS ANGELES NEW YORK SAN FRANCISCO SHANGHAI SINGAPORE SYDNEY TOKYO WASHINGTON, D.C. Reprints.

© Hogan & Hartson LLP. All rights reserved. How We Get to Where We Want to Be – Managing GCP Inspections Pre-Approval Robert F. Church, Partner Hogan &

Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.

Current trends in EU single firm conduct policy and case law

Action Items: Monitoring Off-Label Promotion Do’s and Don’t’s

Blockchain – The Next Great Disruptor?

SHARING CLINICAL DATA: Legal and Privacy Issues

FSMA Enforcement: Focus on Inspections

Personal Liability and Risk Management for

Single Firm Conduct: EU / US convergences and divergences

Brussels, June 6, 2007 Paul E. Kalb, M.D., J.D.

Timothy B. Cleary, Esq. Meredith Manning, Esq.

Research, Experimentation, & Clinical Trials

Presentation transcript:

© Hogan & Hartson LLP. All rights reserved. Pharmaceutical Compliance Forum Clinical Trials Case Study Stephen J. Immelt Thursday, November 8, 2007

© Hogan & Hartson LLP. All rights reserved. 2 FDA FDA as enforcer Form 483 process and expectations Timing False statement potential Warning letter potential Living with the record Broad regulatory powers beyond the particular trial

© Hogan & Hartson LLP. All rights reserved. 3 State Law Enforcement Highly unusual Could be promoted in connection with personal injury actions Subject to local considerations

© Hogan & Hartson LLP. All rights reserved. 4 OIG/DOJ Not classic false claims act situation, but can be motivated to find a hook Aggressive theories could focus on the approval process Numerous points of exposure for false statements Involvement of federal funding at investigator level Subject injury a material, aggravating factor

© Hogan & Hartson LLP. All rights reserved. 5 University Process Typical response for situations involving potential reputational harm No clear process or guidelines Participation or not? Risks Benefits? IRB issues

© Hogan & Hartson LLP. All rights reserved. 6 Congressional Action Intense interest in research related topics Process Privilege Working with staff Dealing with hearings

© Hogan & Hartson LLP. All rights reserved. 7 SEC/FCPA Growing interest in health care arena Heavy government presence in the delivery of health care in many countries creates broad potential exposure Importance of financial controls and oversight Heightened ambivalence about clinical research

© Hogan & Hartson LLP. All rights reserved. 8 Personal Injury Litigation Variety of exposures beyond direct injury Central importance of the study documents – not only consent but also investigator agreement and protocol Importance of rigorous oversight Access issues

© Hogan & Hartson LLP. All rights reserved. 9 Managing the Big Picture Importance of understanding the full range of issues Importance of regulatory process Importance of speed Impact of press scrutiny Dealing with what went wrong

© Hogan & Hartson LLP. All rights reserved. 10 Baltimore Beijing Berlin Boulder Brussels Caracas Colorado Springs Denver Geneva Hong Kong London Los Angeles Miami Moscow Munich New York Northern Virginia Paris Shanghai Tokyo Warsaw Washington, DC For more information on Hogan & Hartson, please visit us at